
Keywords: ضد انعقاد، پادبند; Hemodialysis; rivaroxaban; anticoagulant; anti-FXa activity; atrial fibrillation; stroke; end-stage renal disease (ESRD); area under the curve (AUC); pharmacokinetics; pharmacodynamics; dose finding; dose adjustment; dosing guideline;